![anti stroke meds name anti stroke meds name](https://www.verywellhealth.com/thmb/phg5mF79ZkByaWznU7-7npdsP_U=/5333x4000/smart/filters:no_upscale()/treating-blood-clots-1746090_final-9a9eea79ed4542429fcbd319ba103f7d.jpg)
In the comparison of different statins, moderate- to high-quality evidence indicated that differences between pharmaceutical products seemed modest, with high doses (e.g., atorvastatin 80 mg/day and simvastatin 40 mg/day) associated with the greatest benefits. Statins did not seem to modify all stroke and all-cause mortality outcomes they were associated with a decreased risk of ischemic stroke (odds ratio, OR, 0.81 absolute risk difference, ARD, − 1.6% ), ischemic stroke or TIA (OR, 0.75 ARD, − 4.2% ), and cardiovascular event (OR, 0.75 ARD, − 5.4% ), and did not seem to modify rhabdomyolysis, myalgia, or rise in creatine kinase. The median follow-up period was 2.5 years. We identified nine trials (10,741 patients).
![anti stroke meds name anti stroke meds name](https://ars.els-cdn.com/content/image/1-s2.0-S0163725820302254-gr1.jpg)
Secondary outcomes were different types of strokes, cardiovascular events, and adverse events. Primary outcomes were all-cause mortality and all strokes.
![anti stroke meds name anti stroke meds name](https://www.singlecare.com/blog/wp-content/uploads/2018/12/Brilinta-vs.-Plavix.png)
We used GRADE to rate the overall certainty of evidence.
#Anti stroke meds name trial#
We performed pairwise meta-analyses and trial sequential analyses (TSA) to compare statins versus placebo/no statin, and network meta-analyses using frequentist random-effects models to compare statins through indirect evidence. Two authors extracted data and appraised risks of bias. We searched for randomized controlled trials (RCTs) assessing statins in patients with ischemic stroke or transient ischemic attack (TIA) in MEDLINE, EMBASE, and CENTRAL up to July 2017. We aimed to summarize the evidence for the use of statins in secondary prevention for patients with ischemic stroke by comparing benefits and harms of various statins. Determining which statin to use remains controversial. Statins may prevent recurrent ischemic events after ischemic stroke.